Key Points
June 26 (Reuters) - Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs...
The once-weekly injected drug, retatrutide, is part of a class known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite..
The new family of drugs has reignited interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade...
Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved...
These phase 2 data have given us confidence to further explore the potential of retatrutide in phase 3 trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively, Dan Skovronsky, Lilly's chief scientific and medical officer, said in a statement...
You might be interested in
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
Ozempic on steroids? Successor that could cut down weight in half the time coming soon
14, Nov, 24While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Retatrutide patients lose more weight than Ozempic, Wegovy, or Mounjaro
27, Jun, 23The new weight loss drug, in development by Eli Lilly, could be as powerful as bariatric surgery patients with obesity lost 24% of their body weight.
Weight loss drugs transforming healthcare, may help with addiction
09, Nov, 23A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.